timothy sykes logo
CELC Stock Jumps As VIKTORIA-1 Phase 3 Data Impress Wall Street Thumbnail
G Google News

CELC Stock Jumps As VIKTORIA-1 Phase 3 Data Impress Wall Street

TIM SYKES•UPDATED MAY. 4, 2026, 2:33 PM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Celcuity Inc. surged as promising clinical trial and regulatory progress fueled bullish sentiment, and stocks have been trading up by 15.71 percent.

Candlestick Chart

Live Update At 14:32:26 EDT: On Monday, May 04, 2026 Celcuity Inc. stock [NASDAQ: CELC] is trending up by 15.71%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CELC has been trading like a classic biotech catalyst name. Over the last few weeks, Celcuity shares climbed from around $117 on 2026/04/10 to a recent close near $145 on 2026/05/04, a strong double‑digit percentage move. The daily chart shows a steady staircase higher with sharp bursts around news, not a random grind. That’s what momentum‑focused traders want to see.

Intraday on 2026/05/04, CELC swung between roughly $136 and $151, but held above $145 into the close. That kind of range tells traders there is real emotion and volume behind the tape, yet buyers are still in control by the end of the day.

Under the hood, Celcuity is a classic development‑stage biotech story. The latest quarterly report shows about $165.7M in cash and cash equivalents and roughly $441.5M when you include short‑term investments, against about $321.9M of long‑term debt. A current ratio above 10 and quick ratio near 10 mean CELC is not about to run out of cash tomorrow, even though it posted a net loss of about $50.9M and negative free cash flow near $36.5M. For traders, this mix says “high burn, high potential, but funded through the next catalysts.”

Why Traders Are Watching CELC Now

CELC is front and center on many biotech watchlists because of one thing: gedatolisib. Celcuity’s Phase 3 VIKTORIA‑1 trial in PIK3CA‑mutant HR+/HER2‑ metastatic breast cancer met its primary endpoint, and that is not a small win. In this study, gedatolisib plus fulvestrant, with or without palbociclib, delivered statistically significant and clinically meaningful improvements in progression‑free survival versus alpelisib plus fulvestrant, a key existing standard.

For traders, that language matters. “Statistically significant” says the numbers are solid. “Clinically meaningful” says doctors and payers may care. And CELC is not paying that off with a scary safety profile either; reports describe the regimen as generally well tolerated with a manageable safety picture. That combination often drives real commercial potential in oncology.

CELC is already planning a supplemental NDA with the FDA and will also go to other regulators using these PIK3CA‑mutant data. When you stack these new results on top of earlier positive VIKTORIA‑1 data in PIK3CA wild‑type patients, the story gets bigger. It is no longer just a niche mutation play. Traders are now looking at a possible broad second‑line HR+/HER2‑ advanced breast cancer franchise.

On top of the clinical win, Citizens stepped in with fresh coverage on CELC, tagging it with an Outperform rating and a $150 price target. That target effectively signals confidence that the market still underestimates gedatolisib’s runway, especially with a likely first approval in July for the wild‑type setting and a firm July 17, 2026 PDUFA date already set under Priority Review. For momentum traders, that creates a clear catalyst map to trade around.

More Breaking News

Conclusion

CELC sits at the intersection of a heating tape and a thick catalyst pipeline. The stock’s recent push from the low $120s into the mid‑$140s lines up cleanly with Celcuity’s Phase 3 VIKTORIA‑1 win and growing Street support. The positive PIK3CA‑mutant data, layered on prior wild‑type success, give gedatolisib a believable path toward broad second‑line use in HR+/HER2‑ advanced breast cancer. The planned supplemental NDA and existing Priority Review status lock in multiple regulatory checkpoints through 2026.

At the same time, traders should not ignore the risk profile. CELC is still loss‑making, with negative earnings, negative cash flow, and a price‑to‑book ratio above 60. Return on equity and return on assets are deeply negative. This is a pure execution and data story; any stumble around the July 17, 2026 PDUFA date or future readouts can hit the stock hard.

For active traders who thrive on catalysts, that is exactly the kind of setup that can offer opportunity if managed with discipline. As Tim Sykes loves to remind his students, “Cut losses quickly, because one trade should never make or break you.” As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.”. CELC’s chart, news flow, and balance sheet all say the same thing in a different way: respect the upside, but always know where you are wrong. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading CELC

Millionaire's
POV on CELC

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”